Weiß jemand die WKN ? - 500 Beiträge pro Seite

[Erge]

für diesen OTC-Wert ? (ABRX)

[Kendall1000]

850103

[Kendall1000]

PS Das Kürzel hat sich etwas geändert

Nachlesbar u.a. unter yahoo.con --- finance

[Eurocop2000]

probe

[Erge]

Bei 850103 Bekomme ich die Abott Aktie, meine aber Able Laboratories!

[js200]

Scheint nicht in Deutschland gehandelt zu werden
Hier ein Paar Infos
23.11.01 SCHLUSSKURS 0,29 US/DOLLAR

PR Newswire, 10/01/2001 08:41

Able Laboratories Receives FDA Approval for Lithium Carbonate Capsules USP, 300mg

/FROM PR NEWSWIRE BOSTON 617-482-5355/ [STK] ABRX [IN] MTC [SU] TO BUSINESS AND TECHNOLOGY EDITORS:

Able Laboratories Receives FDA Approval for

Lithium Carbonate Capsules USP, 300mg -- Generic version of Eskalith(TM) with estimated total market of $36 million

SOUTH PLAINFIELD, N.J., October 1 /PRNewswire/ -- ABLE LABORATORIES, INC. (BB:ABRX), today announced it has received Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Lithium Carbonate Capsules USP, 300 mg. The approval followed the FDA`s Division of Bioequivalence determination that Able`s Lithium Carbonate Capsules USP, 300 mg. are bioequivalent and, therefore, therapeutically equivalent to the Eskalith(TM) capsules of SmithKline Beecham Pharmaceuticals. The total generic and brand market for Able`s newly approved drug, a capsule used to treat the manic stage of bipolar disorder (manic-depressive illness), is estimated to be $36 million by IMS Data

Able Laboratories (BB:ABRX) is a developer and manufacturer of generic pharmaceuticals. Since March 2001 Able has received 11 ANDA approvals and one New Drug Approval. The Company has recently completed its transition to focus its activities primarily on generic drug development, manufacturing and sales.

Certain information included in this news release as well as information included in oral statements or other written statements made or to be made by Able Laboratories, Inc., contain statements that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about the Company`s capitalization, anticipated growth and future operations, current or expected market size for the products, the success of current or future product offerings, research and development efforts and the Company`s ability to file for and obtain Food and Drug Administration (FDA) approvals for future products. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that ANDA filings and approvals will be completed and obtained as anticipated. The Company`s forward-looking statements involve important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, actual results may differ materially from those expressed directly, indirectly or implied in any forward-looking statements made by or on behalf of the Company. For a description of additional risks, and uncertainties, please refer to the Company`s filings with the Securities and Exchange Commission, including its registration statement on Form S-3, File No. 333-64734, its Annual Report on Form 10 -KSB for the year ended December 31, 2000 and its quarterly report on Form 10-Q for the quarter ended June 30, 2001.

Eskalith is registered trademark of SmithKline Beecham Pharmaceuticals.

CONTACT:

Catherine M. Frost

Able Laboratories, Inc.

[phone]


PR Newswire, 11/15/2001 18:15

Able Laboratories Conducts Investor Conference Call Thursday, November 15, 2001 To Discuss Third Quarter Results

/FROM PR NEWSWIRE BOSTON 617-482-5355/ [STK] ABRX [IN] MTC HEA BIO [SU] CCA TO BUSINESS AND MEDICAL EDITORS:

Able Laboratories Conducts Investor Conference Call Thursday, November 15,

2001 To Discuss Third Quarter Results

- Conference call available for replay -

SOUTH PLAINFIELD, N.J., Nov. 15 /PRNewswire/ -- ABLE LABORATORIES, INC. (BB:ABRX), today announced its conducted an investor conference call at 4:10 PM EST this afternoon to discuss the Company`s operating results for the third quarter ended September 30, 2001. The conference call was recorded and is available for replay through 5 PM EST, Monday, November 19, 2001 by calling 1-800-625-5288 and referencing ID# 1346912.

Certain information included in this news release (as well as information included in oral statements or other written statements made or to be made by Able Laboratories, Inc. f/k/a DynaGen, Inc.) contain statements that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about the Company`s capitalization, financial performance, ability to conduct its operations, anticipated growth and future operations, current or expected market size for the products, the success of current or future product offerings, research and development efforts and the Company`s ability to file for and obtain Food and Drug Administration (FDA) approvals for future products. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that FDA filings and approvals will be completed as anticipated. The Company`s forward-looking statements involve important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, actual results may differ materially from those expressed directly, indirectly or implied in any forward-looking statements made by or on behalf of the Company. For a description of additional risks, and uncertainties, please refer to the Company`s filings with the Securities and Exchange Commission, including its registration statement on Form S-3, File No. 333-64734, its Annual Report on Form 10 -KSB for the year ended December 31, 2000 and its quarterly report on Form 10-Q for the quarter ended September 30, 2001.

Gruss an alle

JS200

[Erge]

ich brauch aber doch eine WKN, wenn ich in New York kaufen
will. Keiner eine Idee wie die rauskriegt?



Gruß


Erge

[Bottervogel]

886604

[Erge]

Danke!